BeiGene's TEVIMBRA expands for cancer treatment, and BRUKINSA sales soar 107%. See why BGNE stock presents upside potential ...

As it turned out, adding spartalizumab to treatment with the two targeted drugs failed to provide ... to market well behind other PD-1/PD-L1 checkpoint inhibitors – that piggybacking on its ...

Zynyz (retifanlimab) is a late entrant to the PD-1/PD-L1 category ... in its cancer pipeline. CDK2 drug shows promise Those include potential first-in-class CDK2 inhibitor INCB123667, which ...

While some of the initial excitement around immunotherapies has waned, companies—particularly smaller biotechs—are developing ...

The use of SGLT2 inhibitors was associated with a significantly reduced risk for dementia and PD in patients with type 2 diabetes.

Incyte’s blockbuster JAK inhibitor Jakafi has been driving the company’s sales for years now, with this quarter being no ...

Background: Programmed cell death protein 1 (PD-1 ... checkpoint inhibitors. It has been reported that the TCF7 expression in CTLs can be a valuable prognostic factor for determining the response ...

Kanvas Bio Unveils Clinical Data on the Gut Microbiome’s Impact on Anti-Tumoral Immunity at SITC ...

The test improved prediction of patient benefit from anti-PD-1 immune checkpoint inhibitors (ICIs) as a monotherapy and with ...

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination ...

Two first-line cutaneous melanoma patients - one patient who was dose escalated from 70 mg to 210 mg and finally to 350 mg experienced a confirmed partial response (PR) at the higher dose; one patient ...